+ - Tesamorelin is used primarily for reducing abdominal fat
2), aiming to enhance and/or complement the effect of GLP-1 agonism on weight and metabolism [14]
Reproductive and obesity medicine experts tell USA TODAY that theyre also noticing the trend in their offices, and it boils down to two main reasons
Competition will depend on efficacy, dosing, tolerability, supply, price, and indication breadth
More importantly, the hazard ratio for major adverse cardiovascular events (including cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina) for the pooled tirzepatide groups versus glargine was 0.74 (95% CI 0.511.08), suggesting no increased cardiovascular risk with tirzepatide compared to insulin glargine